1. Market Research
  2. > Diagnostics Market Trends
  3. > Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

The Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter royalty financing deals.

Comprehensive directory of royalty financing deals since 2007
Royalty financing contract documents
Royalty financing agreement terms
Royalty financing agreement structure
Top royalty financing deals by value
Most active Royalty financing dealmakers

The Royalty Financing Terms and Agreements report provides comprehensive understanding and unprecedented access to the royalty financing agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter royalty financing partnering deals.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report provides comprehensive access to royalty and revenue financing deals as announced in the life sciences industry since 2007.

This report contains links to online copies of actual royalty financing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of royalty financing dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in royalty financing dealmaking as well as a discussion on the merits and attributes of royalty financing dealmaking.

Chapter 3 provides an overview of the structure of royalty financing deal contracts. The chapter includes numerous case studies to enable understanding of royalty financing deals for royalty assets.

Chapter 4 provides a review of the leading royalty financing deals since 2007. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of royalty financing contract documents since 2007, including deal value, press release and contract document. The chapter is organized by company A-Z.

Chapter 6 provides a comprehensive listing of all royalty financing deal announcements and agreement contracts since 2007 available in the public domain. The chapter is organized by company A-Z and therapeutic area. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in royalty financing dealmaking.

In conclusion, this report provides everything a prospective dealmaker needs to know about royalty financing, enabling thorough learning, education and due diligence prior and during the royalty financing dealmaking process.

Report scope

Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the royalty financing trends and structure of deals entered into by leading biopharma companies worldwide.

Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics includes:

Trends in royalty financing dealmaking in the biopharma industry since 2007
Analysis of royalty financing deal structure
Case studies of real-life royalty financing deals
Comprehensive listing of royalty financing deals since 2007
Access to royalty financing contract documents
The leading royalty financing deals by value since 2007
Most active royalty financing dealmakers since 2007
The leading royalty financing partnering resources

In Royalty Financing Terms and Agreements in Pharma, Biotech and Diagnostics, available contracts are listed by:

Company A-Z
Headline value
Therapeutic area

Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on demand.

Table Of Contents

Royalty Financing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in royalty financing dealmaking

2.1. Introduction
2.2. Difference between royalty and revenue financing deals
2.3. Trends in royalty financing deals since 2007
2.4. Reasons for entering into royalty financing partnering deals
2.5 The emergence of royalty asset purchase deals
2.5.1. Primary players in royalty asset purchase deals
2.5.2. Recent royalty asset purchase deals
2.5.3. The role of big pharma in royalty buyback
2.5.4. The future of royalty asset purchase deals

Chapter 3 - Overview of royalty financing structure

3.1. Introduction
3.2. Anatomy of a royalty asset purchase agreement
3.3. Example royalty financing agreements
3.3.1. Case study 1: Xoma - UCB - Orbimed Advisors - August 2010
3.3.2. Case study 2: Dyax - Paul Capital Healthcare - April 2010
3.3.3. Case study 3: Royalty financing: Biocryst Pharmaceuticals -Shionogi- March 2011
3.3.4. Case study 4: Royalty asset: TPG - CV Therapeutics - April 2008

Chapter 4 - Leading royalty financing deals

4.1. Introduction
4.2. Top royalty financing deals by value
4.3. Top revenue financing deals by value
4.4. Most active royalty financing dealmakers

Chapter 5 - Royalty financing contract documents 2007-2014

5.1. Introduction
5.2. Company A-Z

Chapter 6 - Royalty financing agreement directory 2007-2014

6.1. Introduction
6.2. Company A-Z
6.3. By therapy area

Appendix
Appendix 1 - Royalty financing references
Appendix 2 - Resources
Appendix 3 - Deal type definitions
Appendix 4 - Example royalty financing contract document
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering
Order Form - Upgrades to subscription access products
Order Form - Reports

Table of figures

Figure 1: Definition of royalty assets
Figure 2: Trends in royalty financing deal announcements, 2007-2014
Figure 3: Trends in revenue financing or ‘synthetic royalty' deal announcements, 2007-2014
Figure 4: Leading royalty asset investors
Figure 5: Leading royalty asset purchase agreements
Figure 6: Components of the royalty asset purchase deal structure
Figure 7: Top royalty financing deals by value since 2007
Figure 8: Top revenue financing deals by value since 2007
Figure 9: Most active royalty financing dealmakers 2007-2014
Figure 10: Online partnering resources
Figure 11: Deal type definitions
Figure 12: Royalty financing agreement for Qutenza - April 2010

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

A 33-Country Survey of the Automated Microbiology Market: Supplier Shares, Sales and Volume Forecasts for 100 Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic Tests

  • $ 47 500
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This new 33-country survey from VPGMarketResearch.com contains over 1,000 pages and 550 tables, and provides granular data and analysis not available from ...

A 33-Country Survey of the Cancer Diagnostic Testing Market: Sales Forecasts and Supplier Shares for 40 Tumor Markers--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Strategies, Opportunities

A 33-Country Survey of the Cancer Diagnostic Testing Market: Sales Forecasts and Supplier Shares for 40 Tumor Markers--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Competitive Strategies, Opportunities

  • $ 47 400
  • Industry report
  • February 2016
  • by Venture Planning Group

This report is delivered in 10-15 working days This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, ...

Diagnostics Bundle

Diagnostics Bundle

  • $ 41 225
  • Industry report
  • January 2016
  • by TriMark Publications

The Diagnostics Reports Bundle includes the following TriMark Publications reports at a 15% discount off the individual reports being purchased separately: - Cancer Diagnostic Testing World Markets. ...


Download Unlimited Documents from Trusted Public Sources

Proteomic Market Trends in Europe

  • January 2016
    2 pages
  • Proteomic  

    Protein  

    Cancer  

  • Europe  

View report >

Diagnostics Forecast Statistics

  • January 2016
    3 pages
  • In Vitro Diagno...  

    Drug Testing  

    Drug Test  

View report >

Protein Industry in the Netherlands

  • January 2016
    2 pages
  • Drug Design  

    Protein  

    X-ray  

  • Netherlands  

View report >

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.